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Effects of Intraduodenal Infusions of 
L-phenylalanine and L-glutamine on 
Antropyloroduodenal Motility and Plasma 
Cholecystokinin in Healthy Men
Robert E Steinert,1* Maria F Landrock,1 Michael Horowitz,1,2 and Christine Feinle-Bisset1,2
1Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; and 2NHMRC Center of Research Excellence 
in Translating Nutritional Science to Good Health, Adelaide, Australia
Background/Aims
Dietary proteins have potent eating-inhibitory and glucose-lowering effects, which may be mediated via effects of amino acids 
on gastrointestinal hormone and motor function, although little information is available. We have now evaluated the effects 
of L-phenylalanine (L-Phe) and L-glutamine (L-Gln) on antropyloroduodenal motility and plasma cholecystokinin (CCK) concen-
trations.
Methods
Two double-blind, 3-way cross-over studies were performed, each including 10 healthy, normal-weight men. We determined 
the antropyloroduodenal motor and plasma CCK responses to 90-minute intraduodenal infusions of L-Phe (study A) or L-Gln 
(study B), each at 0.15 kcal/min (total 13.5 kcal), or 0.45 kcal/min (total 40.5 kcal), or saline (control), in randomized fashion.
Results
Intraduodenal L-Phe at 0.45 kcal/min, but not at 0.15 kcal/min, suppressed antral (P < 0.01), and stimulated phasic (P <  
0.01), but not tonic, pyloric, or duodenal pressures, while L-Phe at both 0.15 kcal/min and 0.45 kcal/min stimulated plasma 
CCK. In contrast, L-Gln had no effect on antral, duodenal or pyloric pressures, or plasma CCK.
Conclusions
Intraduodenal infusions of L-Phe and L-Gln, in doses of 0.15 kcal/min and 0.45 kcal/min for 90 minutes, have different effects
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on antropyloroduodenal motility and CCK in normal-weight men. The modulation of antral and pyloric pressures and CCK may 
contribute to the eating-inhibitory effects of oral L-Phe, possibly through the slowing of gastric emptying.
(J Neurogastroenterol Motil 2015;21:404-413)
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Introduction
It is increasingly recognised that the effects of protein on up-
per gastrointestinal (GI) motor and hormone function contribute 
to the effects of dietary protein to diminish energy intake and im-
prove postprandial glycaemic control.1-5 For example, we recently 
found that acute ingestion of 55 g whey protein prior to a mash-
ed-potato meal slowed gastric emptying, stimulated insulin, and 
reduced postprandial blood glucose in type 2 diabetic patients.4 
Furthermore, high-protein meals, when compared with isocaloric 
meals high in fat or carbohydrate, reduced energy intake, in both 
lean and obese subjects, and this was associated with a sustained 
stimulation of plasma cholecystokinin (CCK).2
It is well established that CCK modulates upper gut func-
tions, including antropyloroduodenal (APD) motility, gastric 
emptying, and pancreatic secretion.6-9 For example, exogenous 
administration of CCK stimulates tonic and phasic pyloric pres-
sures in healthy men,6 and loxiglumide, a CCK receptor antago-
nist, markedly accelerates gastric emptying of both solids and liq-
uids in healthy volunteers.8
The release of fatty acids from triglycerides during digestion 
is critical for the effects of fat on upper GI motility, gastric emp-
tying, and gut hormone release,10-14 and it appears that digestion 
of protein to amino acids is a similar prerequisite.15 A number of 
amino acids have been reported to affect APD motility and gut 
hormone secretion. For example, intraduodenal (ID) L-trypto-
phan (L-Trp) stimulates pyloric pressures,16,17 as well as the se-
cretion of gut hormones, including CCK,16 at loads as low as 0.15 
kcal/min given for 90 minutes to healthy lean men. L-phenyl-
alanine (L-Phe) and L-glutamine (L-Gln) have also been re-
ported to affect aspects of gut motor and hormone functions. For 
example, L-Phe, when administered orally in amounts of up to 10 
g, potently increased plasma CCK in humans,18 while L-Gln, ad-
ministered ID at a load amounting to 15 g and in the presence of 
glucose, stimulated pyloric pressures in healthy subjects and type 
2 diabetic patients.19
The effects of L-Phe and L-Gln on APD motility, partic-
ularly the activity of the pylorus, which is the major determinant 
of the slowing of gastric emptying, and the relationship with the 
magnitude of the stimulation of CCK, have not been investigated 
comprehensively. We hypothesized that increasing ID loads of 




Two double-blind, 3-way crossover studies were performed, 
each in 10 healthy, normal-weight men (study A: mean age 23.6 
± 2.0 years [range 18-40], body mass index [BMI] 22.5 ± 0.6 
kg/m2 [range 19.4-25.0]; study B: mean age 27.2 ± 3.9 years 
[range 18-48], BMI 22.5 ± 0.7 kg/m2 [range 18.5-25.3]) (Fig. 
1). Exclusion criteria were smoking, consumption of > 20 g of 
alcohol/day, any medical condition, GI symptoms, and the use of 
medications known to affect GI function. The study protocol was 
approved by the Royal Adelaide Hospital Research Ethics 
Committee and carried out in accordance with the Declaration of 
Helsinki. Each subject provided informed written consent prior 
to their enrolment.
Study Design and Protocol
Subjects were studied on three occasions each, separated by 
3-10 days, on which they received, in randomized, double-blind 
fashion, 90-minute ID infusions of either L-Phe at (i) 0.15 
kcal/min (“L-Phe 0.15”), or (ii) 0.45 kcal/min (“L-Phe 0.45”), 
or (iii) control (study A); or L-Gln at (i) 0.15 kcal/min (“L-Gln 
0.15”), or (ii) 0.45 kcal/min (“L-Gln 0.45”), or (iii) control 
(study B). The lower load was chosen based on the dose of L-Trp 
shown to be effective in stimulating plasma CCK and pyloric 
pressures in our previous study16 while the higher load equated to 
the load of 10 g of L-Phe, which was reported to stimulate plasma 
CCK.18 Amino acid solutions were prepared by dissolving (i) 3.3 
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Figure 1. Experimental design of studies A and B each including 10 
healthy, normal-weight men. Subjects were studied on three occasions 
on which they received, in randomized, double-blind fashion, a 
90-minute intraduodenal (ID) infusion of either L-phenylalanine 
(L-Phe) at (i) 0.15 kcal/min, or (ii) 0.45 kcal/min, or (iii) control (study 
A); or L-glutamine (L-Gln) at (i) 0.15 kcal/min, or (ii) 0.45 kcal/min, 
or (iii) control (study B). Antropyloroduodenal motility was recorded 
continuously and blood samples were collected for measurements of 
plasma cholecystokinin at regular time intervals from t = −10 minutes 
until t = 90 minutes.
g, or (ii) 9.9 g crystalline L-Phe or L-Gln (PureBulk, Roseburg, 
OR, USA), 118.3 mg CaCl2 × 2H2O and NaCl (3.8 g and 2.3 g 
in study A, and 3.6 g and 2.1 g in study B, respectively, to achieve 
isotonic (300 mosm) solution) in 405 mL distilled water. The iso-
tonic control solution contained 118.3 mg CaCl2 × 2H2O and 
4.6 g NaCl in 405 mL distilled water. All solutions were ad-
ministered at a rate of 4.5 ml/min. A research officer, who was not 
otherwise involved in the performance of the studies or data ana-
lysis, prepared the solutions.
Subjects were instructed to abstain from alcohol and stren-
uous exercise for 24 hours, and provided with a standardized 
meal (Beef Lasagne, McCain Food, Wendouree, Victoria, 
Australia; total energy content: 1160 kcal) to be consumed at 
19:00 the night before each visit. Subjects then fasted overnight 
from any further solids and liquids, except water, until they at-
tended the laboratory at 08:30 the following day. On arrival, a 
small-diameter (3.5 mm), 17-channel manometric catheter (total 
length: 100 cm; Dentsleeve International, Mui Scientific, Missi-
ssauga, Ontario, Canada) was inserted into the stomach through 
an anaesthetized nostril and allowed to pass into the duodenum 
by peristalsis. The catheter contained 16 side-holes, spaced at 1.5 
cm intervals, to measure pressures in the APD region. Six 
side-holes (channels 1-6) were positioned in the antrum, a 4.5 cm 
sleeve-sensor (channel 7) with 2 channels (channels 8 and 9) on 
the back of the sleeve was positioned across the pylorus, and 7 
channels (channels 10-16) were positioned in the duodenum. 
The correct positioning of the catheter, with the sleeve sensor 
straddling the pylorus, was maintained by continuous measure-
ment of the transmucosal potential difference between the most 
distal antral channel (channel 6: approximately −20 mV) and 
the most proximal duodenal channel (channel 10: approximately 
+10 mV).20 The manometric channels were perfused with de-
gassed, distilled water, except for the transmucosal potential dif-
ference channels, which were perfused with degassed 0.9% saline, 
at 0.15 mL/min. An additional channel, used for ID infusion of 
amino acid and control solutions, was located 14.5 cm distal to the 
pylorus.
Once the catheter was positioned correctly, fasting motility 
was observed until the occurrence of phase III of the inter-
digestive migrating motor complex. Immediately after the end of 
phase III, during motor quiescence (ie, phase I of the migrating 
motor complex), an intravenous cannula was placed in a forearm 
vein for blood sampling with baseline blood sample (t = −10 
minutes) taken and baseline motility recording obtained (t = 
−10-0 minutes). At t = 0 minute, another blood sample was 
taken and ID infusions of amino acids or control (study A: 
L-Phe, study B: L-Gln), commenced and were continued for 90 
minutes (ie, from t = 0-90 minutes). APD motility was recorded 
continuously and blood samples for measurements of plasma 
CCK were collected at every 15 minuts. At t = 90 minutes, the 
infusion was terminated and the manometric catheter and the in-
travenous cannula removed, and the subject was allowed to leave 
the laboratory.
Measurements
Blood samples were collected into ice-chilled ethylenedi-
aminetetraacetic acid (EDTA) tubes. Plasma was then separated 
by centrifugation at 3200 rpm for 15 minutes at 4°C within 15 
minutes of collection and stored at −70°C until assayed. Plasma 
CCK-8 (pmol/L) was measured by radioimmunoassay after etha-
nol extraction using an adaptation of the method of Santangelo et 
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al.21 Standards were prepared using synthetic sulfated CCK-8 
(Sigma Chemical, St Louis, MO, USA) and an anti CCK-8 anti-
body (C2581, Lot 105H4852; Sigma Chemical). This antibody 
binds all CCK peptides containing the sulfated tyrosine residue in 
position 7, showing a 26% cross-reactivity with unsulfated 
CCK-8, less than 2% cross-reactivity with human gastrin I, and 
does not bind to structurally unrelated peptides. Sulfated CCK-8 
125I-labeled with Bolton and Hunter reagent (Perkin Elmer, 
Boston, MA, USA) was used as tracer, and samples were in-
cubated for 7 days at 4oC. The antibody-bound fraction was sepa-
rated by the addition of dextran-coated charcoal containing gela-
tin and the radioactivity determined in the supernatants following 
centrifugation. Intra- and inter-assay coefficients of variation 
were 8.3% and 12.6%, respectively. The detection limit was 1 
pmol/L.
APD motility was recorded and digitized using a computer- 
based system that ran commercially available software (Solar GI, 
Medical Measurement Systems Database software version 8.17, 
Medical Measurement Systems, Enschede, The Netherlands). 
Data were analysed for (1) the number and amplitude of antral 
and duodenal pressure waves (PWs), (2) the number and ampli-
tude of isolated pyloric pressure waves (IPPWs), and (3) basal 
pyloric pressure (BPP), using custom-written software modified 
to our requirements (Prof. André Smout, Department of Gastro-
enterology, Academic Medical Center, Amsterdam, Netherlands). 
Phasic PWs were defined by an amplitude > 10 mmHg with a 
minimum time interval of 15 seconds between peaks for antral 
and pyloric waves and 3 seconds for duodenal waves.22,23 BPP 
was calculated by subtracting the mean basal pressure (with pha-
sic pressures excluded) recorded at the most distal antral channel 
from the mean basal pressure recorded at the sleeve.20
Data Analysis and Statistical Methods 
The number of subjects was determined by power calcu-
lations based on our previous study with ID L-Trp.16 We calcu-
lated that with 10 subjects we would be able to detect a significant 
difference in the maximum number of isolated pyloric pressure 
waves per 15 minutes of 15 at  = 0.05, with a power of 80%, 
within groups.
Baseline values for antral, duodenal and pyloric pressures as 
well as plasma CCK were calculated as means of values obtained 
between t = −10 to t = 0 minute. During infusions, the number 
and amplitude of IPPWs and BPP were expressed as mean val-
ues over 15-minute periods. The number and amplitude of antral 
and duodenal PWs were used to calculate antral and duodenal 
motility indices (MI), using the equation: MI (mmHg × num-
ber) = ln[(sum of amplitudes x number of phasic PWs)] + 1.24 
The number, amplitude, and MI of antral and duodenal PWs 
were expressed as mean values over the entire 90-minute infusion 
period.
Statistical analysis was performed using SPSS software 
(version 19.0, SPSS, Chicago, IL). BPP, IPPWs, and plasma 
CCK were analyzed by repeated-measures two-factor analysis of 
variance (ANOVA), with time (0-90 minutes) and treatment 
(L-Phe 0.15, L-Phe 0.45, control, or L-Gln 0.15, L-Gln 0.45, 
control) as factors. The number, amplitude and MI of antral and 
duodenal PWs were analyzed by one-factor ANOVA. Post-hoc 
comparisons, adjusted for multiple comparisons by Bonferroni’s 
correction, were performed, where ANOVAs revealed significant 
effects, between either dose of amino acid versus control, as the 
primary focus of this study. Correlations among area under the 
curves (AUCs, calculated by using the trapezoidal rule) for CCK 
with AUC for IPPWs and BPP and with antral and duodenal 
pressures, as well as with the amino acid load, were assessed using 
linear within-subject correlation analysis corrected for repeated 
measures.25 To assess differences in effects between the two ami-
no acids, we compared the above parameters, corrected for values 
obtained during control, at the load of 0.45 kcal/min, using un-
paired t tests. R values > 0.5 were considered physiologically 
relevant. All data are reported as means ± SEM. All tests were 
two-tailed, and differences were considered statistically sig-
nificant at P < 0.05.
Results
In both studies, all subjects completed all 3 study visits, and 
the study conditions were well tolerated, with no subject experi-
encing adverse effects. All data are from all subjects (n = 10), 
with the exception of basal pyloric pressures in study A (L-Phe), 
for which data analysis was not possible in 2 subjects, due to tech-
nical problems.
Study A: Effects of L-phenylalanine
Antropyloroduodenal pressures
Baseline values for antral, duodenal and pyloric pressures did 
not differ among study days (data not shown). 
Antral pressures. There was an effect of treatment on the 
mean amplitude (P < 0.01) and the MI (P < 0.01), but not the 
total number, of antral PWs (Table 1). L-Phe 0.45 and L-Phe 
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Table 1. Effects of Intraduodenal Infusions of L-Phenylalanine (Study A) or L-Glutamine (Study B), Each at Loads of 0.15 kcal/min or 0.45 
kcal/min, or Saline Control, Each for 90 Minutes at a Rate of 4 mL/min, on Antral and Duodenal Pressures
Control 0.15 kcal/min 0.45 kcal/min P-value
L-phenylalanine
    Antral pressures
        Number   76 ± 12 60 ± 12  38 ± 12 NS
        Amplitude (mmHg) 60 ± 10 31 ± 5a  22 ± 4a < 0.001
        MI (mmHg) 12 ± 1 11 ± 1    9 ± 1a < 0.01
    Duodenal pressures
        Number 466 ± 55 443 ± 52 490 ± 55 NS
        Amplitude (mmHg) 27 ± 1 30 ± 3 28 ± 2 NS
        MI (mmHg) 16 ± 0 16 ± 0 16 ± 0 NS
L-glutamine
    Antral pressures
       Number 97 ± 20   90 ± 18  70 ±11 NS
       Amplitude (mmHg) 50 ± 7 43 ± 8 29 ± 4 NS
       MI (mmHg) 13 ± 1 12 ± 1 12 ± 0 NS
    Duodenal pressures
      Number 609 ± 110 620 ± 73 522 ± 62 NS
      Amplitude (mmHg) 24 ± 1 25 ± 2 24 ± 2 NS
      MI (mmHg) 16 ± 0 16 ± 0 16 ± 0 NS
MI, motility index, NS, not significant.
aP < 0.05 vs control. Data are means ± SEM (n = 10) healthy mean in each of study. 
0.15 reduced the amplitude, and L-Phe 0.45, but not L-Phe 
0.15, reduced the MI, of antral PWs compared with control.
Basal pyloric pressure. There was no effect of treatment 
on BPP (Fig. 2A).
Isolated pyloric pressure. There was an effect of treat-
ment on the number (P < 0.05) (Fig. 2B), but not the amplitude 
(Fig. 2C), of IPPWs. The mean number of IPPWs was higher 
during L-Phe 0.45, but not L-Phe 0.15, compared with control, 
however, post-hoc comparisons revealed no significant differences 
between treatments.
Duodenal pressures. There was no effect of treatment on 
the total number, mean amplitude, or the MI, of duodenal PWs 
(Table 1).
Plasma cholecystokinin concentrations
Baseline plasma concentrations did not differ among study 
days. There was a treatment × time interaction (P < 0.05) for 
plasma CCK (Fig. 3A). L-Phe 0.45 increased plasma CCK 
promptly at 15 minutes, and the effect was sustained until t = 90 
minutes compared with control. L-Phe 0.15 increased plasma 
CCK at 15-30 minutes and at 60 minutes and 90 minutes com-
pared with control.
Correlations between the load of L-phenylalanine, 
antropyloroduodenal motility, and plasma 
cholecystokinin
There was a negative correlation between the dose of L-Phe 
and the total number (r = −0.50, P < 0.05), mean amplitude (r 
= −0.67, P < 0.001) and MI (r = −0.63, P < 0.05) of antral 
PWs, and a positive correlation between the dose of L-Phe and 
the AUC for the number of IPPWs (r = 0.52, P < 0.05) and 
the AUC for plasma CCK (r = 0.71, P < 0.001). In addition, 
the AUC for plasma CCK was inversely related to the mean am-
plitude of antral PWs (r = −0.65, P = 0.001).
Study B: Effects of L-glutamine
Antropyloroduodenal pressures
Baseline values for antral, duodenal and pyloric pressures did 
not differ among study days (data not shown).
Antral pressures. There was no effect of treatment on the 
total number, mean amplitude, or the MI, of antral PWs (Table 1).
Basal pyloric pressure. There was no effect of treatment 
on BPP (Fig. 2D).
Isolated pyloric pressure. There was no effect of treatment 
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Figure 2. Basal pyloric pressure (BPP) 
(A, D), and number (B, E), and 
amplitude (C, F) of isolated pyloric 
pressure waves (IPPWs) during 90- 
minute intraduodenal (ID) infusions of 
L-phenylalanine (L-Phe; A, B, C), or 
L-glutamine (L-Gln; D, E, F), at (1) 
0.15 kcal/min (L-Phe 0.15 or L-Gln 
0.15), or (2) 0.45 kcal/min (L-Phe 0.45) 
or (L-Gln 0.45), or saline control. 
Repeated-measures analyses of variance, 
with treatment and time as factors, were 
used to assess differences in BPP and 
IPPWs. Post-hoc comparisons, adjusted 
for multiple comparisons by Bonferroni’s
correction, were used to determine signi-
ficant differences between either dose and 
control. B: Treatment effect (P < 0.05). 
Data are means ± SE (n = 10), except 
for study A (n = 8).
on the number (Fig. 2E), or amplitude (Fig. 2F), of IPPWs.
Duodenal pressures. There was no effect of treatment on 
the total number, mean amplitude, or the MI, of duodenal PWs 
(Table 1). 
Plasma cholecystokinin concentrations
Baseline plasma concentrations did not differ among study 
days. There was no effect of L-Gln on plasma CCK concen-
trations (Fig. 3B).
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Figure 3. Plasma cholecystokinin (CCK) during 90-minute intraduodenal (ID) infusions of L-phenylalanine (L-Phe; A), or L-glutamine (L-Gln; 
B), at (1) 0.15 kcal/min (L-Phe 0.15 or L-Gln 0.15), or (2) 0.45 kcal/min (L-Phe 0.45 or L-Gln 0.45), or saline control. Repeated-measures analyses 
of variance, with treatment and time as factors, were used to assess differences in cholecystokinin. Post-hoc comparisons, adjusted for multiple 
comparisons by Bonferroni’s correction, were used to determine significant differences between either dose and control. A: Treatment × time 
interaction (P < 0.05); *L-Phe 0.45 vs control, †L-Phe 0.15 vs control. Data are means ± SE (n = 10).
Table 2. Comparative Effects of Intraduodenal Infusions of L-Phenylalanine (Study A) or L-Glutamine (Study B), at 0.45 kcal/min, for 90 Minutes 
at a Rate of 4 mL/min, on Antropyloroduodenal Motility and Cholecystokinin Secretion
L-Phenylalanine L-Glutamine P-value
Antral pressures (change from control)
    Number −38 ± 16 −28 ± 20 NS
    Amplitude (mmHg) −38 ± 11 −20 ± 9 NS
    MI (mmHg) −2.8 ± 0.9 −1.3 ± 0.6 NS
Duodenal pressures (change from control)
    Number 24 ± 77 −87 ± 142 NS
    Amplitude (mmHg) 1 ± 1 1 ± 2 NS
    MI (mmHg) 0.1 ± 0.3 −0.2 ± 0.4 NS
Basal pyloric pressures (change from control)
    AUC 50 ± 70 74 ± 55 NS
Isolated pyloric pressure waves (change from control)
    AUC Number 513 ± 213 119 ± 148 NS
    AUC Amplitude (mmHg) 487 ± 209 227 ± 235 NS
CCK (change from control)
    AUC 74.6 ± 13.9 26.9 ± 16.6 < 0.05
MI, motility index; AUC, area under the curve; CCK, cholecystokinin.
Data are means ± SEM (n = 10, except for basal pyloric pressure in study A [n = 8]).
Correlations between the load of L-glutamine, 
antropyloroduodenal motility, and plasma 
cholecystokinin
There were no correlations between antral, pyloric or duode-
nal pressures, or plasma CCK, and the load of L-Gln ad-
ministered, or between the AUC for plasma CCK and antral, du-
odenal or pyloric pressures.
Comparative effects between L-phenylalanine and 
L-glutamine
There were no significant differences in antral, tonic or pha-
sic pyloric, or duodenal pressures, between L-Phe and L-Gln ad-
ministered at 0.45 kcal/min, although mean values for tonic and 
phasic pyloric pressures were markedly higher during L-Phe 
than L-Gln (Table 2). Plasma CCK concentrations were greater 
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during L-Phe, when compared with L-Gln (P < 0.05).
Discussion
We have investigated the effects of acute ID administration 
of two amino acids, L-Phe and L-Gln, on APD motility and 
plasma CCK in healthy men. We found that while L-Phe sup-
pressed antral pressure, stimulated phasic pyloric pressure, and 
increased plasma CCK, in a dose-dependent manner, there was 
no effect of L-Gln in identical dosage on these outcomes. These 
observations, accordingly, establish that the effects of amino acids 
on upper GI function are distinct.
The findings relating to the effect of L-Phe on plasma CCK 
are consistent with earlier reports; Ballinger and Clark18 found 
that in healthy men 10 g of orally administered L-Phe increased 
plasma CCK about 5-fold within 20 minutes. Our data show that 
when infused directly into the small intestine at a constant rate of 
0.45 kcal/min over 90 minutes (totalling 9.9 g), L-Phe also stim-
ulates the release of CCK. However, there were 2 major differ-
ences: (1) while plasma CCK peaked within 15 minutes, the in-
crease was only about 1.5-fold, which is much less than reported 
previously,18 but comparable to that observed in our recently 
published study with 3.3 g (0.15 kcal/min) of L-Trp, also infused 
over 90 minutes,16 and (2) in contrast to orally administered 
L-Phe18 we found that in response to ID L-Phe, plasma CCK 
concentrations remained elevated over the 90-minute infusion 
period. One explanation for the latter may be the fixed rate at 
which L-Phe was infused in our study, providing a weaker, but 
more constant, stimulus over 90 minutes. We are not aware of 
studies that have evaluated the course of gastric emptying of 
L-Phe over time, however Carney and colleagues26 reported that 
while oral ingestion of L-Trp (~3 g as isotonic aqueous solution) 
markedly slowed gastric emptying (as measured scintigraphi-
cally), compared with control (isotonic saline), more than 10% of 
the solution (ie, > 1.2 kcal) was emptied within the first 15 
minutes. This relatively large initial rate of emptying would be 
anticipated to cause substantial stimulation of small intestinal re-
ceptors, and this is very likely to also be the case with oral L-Phe, 
leading to substantial CCK release. That the latter effect was 
much less pronounced in our ID study, is likely to be attributable 
to the lower infusion rate. In addition, orosensory stimulation27 
and gastric distension28 may contribute to CCK release in re-
sponse to oral L-Phe.
There was no increase in plasma CCK in response to L-Gln, 
and we are unaware of any other studies in humans that have eval-
uated the effect of L-Gln as a CCK secretagogue. In contrast, or-
al and ID L-Gln (although administered in much larger doses of 
15-30 g) elevated plasma glucagon-like peptide-1 (GLP-1) con-
centrations, in healthy, obese, and type 2 diabetic subjects.19,29,30 
Our observations suggest that the effect of amino acids on CCK 
secretion (at loads of up to 10 g) depends on the chemical charac-
teristics of the amino acid. We have demonstrated recently that 
also L-Trp potently stimulates CCK secretion,16 thus, aromatic 
amino acids appear to be potent CCK secretagogues. This is in 
line with earlier studies showing that aromatic amino acids modu-
late upper GI function including biliopancreatic secretion, upper 
intestinal motility and gastrin and gastric acid secretion.18,31-36 
Whether the different secretory responses are related to different 
amino acids transport mechanisms or luminal amino acids re-
ceptors, however, requires further research. 
We also evaluated the effect of L-Phe and L-Gln on APD 
motility. In previous studies, ID (~0.4 g over 20 minutes) and 
oral (~3 g) doses of L-Trp stimulated pyloric motility, reduced 
duodenal motility17 and slowed gastric emptying26 in humans. 
Our own recent study with L-Trp, infused ID at 0.15 kcal/min 
over 90 minutes (total load: 3.3 g), confirmed these findings and 
also demonstrated a relationship between both, tonic and phasic, 
pyloric pressures with plasma CCK.16 We can only speculate on 
possible reasons for the lack of a relationship between plasma 
CCK and pyloric pressures in study A, however the more moder-
ate increase in plasma CCK during infusion of L-Phe is likely to 
be one explanation. This may also explain the overall lack of 
L-Phe on tonic pyloric pressures. We found, however, a marked 
reduction in antral pressure waves during infusion of L-Phe, 
which correlated well with increases in plasma CCK, suggesting 
that the amount of CCK released was sufficient to significantly 
suppress antral motility. A direct comparison of the effects of 
L-Phe and L-Gln on antral motility across both studies (A and 
B) showed, however, no significant difference, possibly because 
of the small number of subjects included, although we identified 
a significant difference between L-Phe and L-Gln on CCK 
secretion. A comparison of the magnitude of the effects of L-Phe 
on APD motility and CCK secretion with the effects seen in re-
sponse to ID protein, glucose, fat or free fatty acids in our pre-
vious studies with similar experimental designs reveals that the 
APD and CCK responses to L-Phe are rather small.3,37-39 
However, it needs to be recognised that while free fatty acids 
were administered at comparable loads of 0.4 kcal/min,39 protein, 
carbohydrate and fat were administered in much higher caloric 
loads of up to 4 kcal/min.3,37,38
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We have recently identified an important role of phasic py-
loric pressures and plasma CCK as independent determinants of 
energy intake in response to ID lipid and carbohydrate infu-
sions.40 Although we do not relate the present data to effects on ad 
libitum eating, our findings contribute to a better understanding 
of the mechanisms underpinning the pronounced satiating ca-
pacity of high-protein diets. The stimulation of CCK and modu-
lation of antral and phasic pyloric motility by L-Phe, like L-Trp, 
are likely to contribute to protein-induced satiation. Thus, the 
roles of dietary amino acids and proteins in the regulation of upper 
GI functions and energy intake warrant much further research.
We used an ID infusion paradigm to administer L-Phe and 
L-Glu, thus our study has a number of limitations that require 
consideration; while ID infusion (1) avoids potentially confound-
ing factors, such as the substantial interindividual variations in 
gastric emptying, it is unable to mimic normal gastric emptying 
with initial periods of rapid emptying and exponential declines 
over time as well as pulsatile movements, and (2) allows direct 
stimulation of small intestinal nutrient receptors, bypassing the 
stomach and thus, not initiating gastric signals (eg, distension) 
that may modulate upper GI function.
In conclusion, acute ID administration of L-Phe, but not 
L-Gln, in a dose of 0.45 kcal/min, suppressed antral pressures, 
stimulated phasic pyloric pressures, and increased plasma CCK, 
in a dose-dependent manner in healthy men, indicating that ami-
no acids vary in their effects. Our observations have important 
implications for an improved understanding of the contributions 
of dietary nutrients, particularly amino acids, to the regulation of 
GI functions, and much further research is required to unravel 
the role of the different amino acids in the regulation of these 
functions and the relationships with the marked eating-inhibitory 
effect of high-protein diets.
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